Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть